Building a bridge to a COVID-19 vaccine

Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.  George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,” said Yancopolous.  Speaking exclusively to Axel Threlfall, Reuters Editor at Large, Yancopolous added that if the therapy is proven to be effective, significant doses could be rapidly made available to those who have been hospitalised.   “There are already of the order of hundreds of thousands or a million doses that could be put to use very soon for people in hospital, people on ventilators. We could produce more doses every month.” Proven approach At the same time Regeneron is also working on large-scale manufacturing of an antibody cocktail therapy which has the potential to enter human clinical studies by June. The hope is that this can be administered as prophylaxis before exposure to the virus or to treat those already infected. “We are using technology and approaches that have worked before…saving patients with Ebola. The technologies and our peo...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news